Citations 164

Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma

Cancer Research | February 1, 2019 | Volume: 79 | Issue: 8 | Pages: 2065-2071

10.1158/0008-5472.can-18-2888 | PMID 30709929

Abstract Genome-wide association studies (GWAS) have so far identified 25 loci associated with glioma risk, with most showing specificity for either glioblastoma (GBM) or non-GBM tumors. The majority of these GWAS susceptibility variants reside in noncoding regions and the causal genes underlying the associations are largely unknown. Here we performed a transcriptome-wide association study to search for novel risk loci and candidate causal genes at known GWAS loci using Genotype-Tissue Expression Project (GTEx) data to predict cis-predicted gene expression in relation to GBM and non-GBM risk in conjunction with GWAS summary statistics on 12,488 glioma cases (6,183 GBM and 5,820 non-GBM) and 18,169 controls. Imposing a Bonferroni-corrected significance level of P < 5.69 × 10−6, we identified 31 genes, including GALNT6 at 12q13.33, as a candidate novel risk locus for GBM (mean Z = 4.43; P = 5.68 × 10−6). GALNT6 resides at least 55 Mb away from any previously identified glioma risk variant, while all other 30 significantly associated genes were located within 1 Mb of known GWAS-identified loci and were not significant after conditioning on the known GWAS-identified variants. These data identify a novel locus (GALNT6 at 12q13.33) and 30 genes at 12 known glioma risk loci associated with glioma risk, providing further insights into glioma tumorigenesis. Significance: This study identifies new genes associated with glioma risk, increasing understanding of how these tumors develop.
Using germline variants to estimate glioma and subtype risks

Neuro-Oncology | January 8, 2019 | Volume: 21 | Issue: 4 | Pages: 451-461

10.1093/neuonc/noz009 | PMID 30624711

Loss of BAP1 and PBRM1 expression in non-clear cell renal cell carcinomas compared to clear cell renal cell carcinomas.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4529-4529

10.1200/jco.2014.32.15_suppl.4529

Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 509-509

10.1200/jco.2014.32.15_suppl.509

Association of loss of BAP1 expression in cell renal cell carcinomas with PDL1 expression.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4530-4530

10.1200/jco.2014.32.15_suppl.4530

COMP-05. EVALUATION OF A DEEP LEARNING ARCHITECTURE FOR MRI PREDICTION OF IDH, 1p19q AND TERT IN GLIOMA PATIENTS

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi64-vi64

10.1093/neuonc/noy148.260

GENE-23. PREVIOUSLY IDENTIFIED COMMON GLIOMA RISK SNPs ARE ASSOCIATED WITH FAMILIAL GLIOMA

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi108-vi108

10.1093/neuonc/noy148.449

EPID-12. USING GERMLINE VARIANTS TO PREDICT GLIOMA RISK AND IDENTIFY GLIOMA SUBTYPE PRE-OPERATIVELY

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi82-vi82

10.1093/neuonc/noy148.339

GENE-29. DLL3 AND ETV1 ARE INACTIVATED/METHYLATED IN CIC WILD-TYPE, IDH-MUTATED, 1p/19q-CODELETED GLIOMA

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi109-vi109

10.1093/neuonc/noy148.455

TMOD-18. THE PATIENT DERIVED XENOGRAFT NATIONAL RESOURCE: A COMPREHENSIVE COLLECTION OF HIGH-GRADE GLIOMA MODELS FOR PRE-CLINICAL AND TRANSLATIONAL STUDIES

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi272-vi272

10.1093/neuonc/noy148.1130